$DRIO

DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Lawrence Leisure notified the Board of Directors (the “Board”) of DarioHealth Corp. (the “Company”) o

DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on July 10, 2026, the temporary medical leave of absence of Steven Nelson, President and Chief Com

DarioHealth Corp. discussed its Q2 2026 earnings call, saying it is shifting from an investment phase to compounding growth via account depth, partner distribution, AI (DarioIQ), and value chain participation. It exited lower-quality pharma services for higher-margin B2B2C revenue. Contracted/late-stage ARR of $13.1M should convert in H2 2026, mainly 2027. Pro forma cash is $36.8M after a $22.8M registered direct financing.

DarioHealth (DRIO) CEO Erez Raphael discussed the company’s positioning and growth drivers in a Q2 2026 earnings call transcript. He described a multi-condition digital health platform with FDA-cleared connected devices, proprietary longitudinal data (about 13 billion data points), and AI (DarioIQ). The company said DarioIQ could add about 10% to 15% to recurring revenues from existing customers over time.

DarioHealth (NASDAQ:DRIO) said in its Q2 earnings call that sequential revenue fell due to post-transformation cleanup and closure of its pharmaceutical channel, with management expecting momentum to build in Q3-Q4 and accelerate in Q1 2027. The company highlighted channel-partner account growth, AI DarioIQ potential to lift recurring revenue 10%-15%, and $14M cash at June 30 plus $22.8M net proceeds from July financing.

DarioHealth Corp. (NASDAQ: DRIO) reported Q2 2026 revenue of $5.2 million, down from $5.6 million in Q1 2026, citing discontinuation of some pharmaceutical-related business. Gross margin rose to 62% (from 57% in Q1 2026). Operating loss improved 30% YoY and 11% QoQ. Pro forma cash was $36.8 million after July 2026 at-the-market financing.

DarioHealth Corp. (NASDAQ: DRIO) said it expanded its provider-backed cardiometabolic platform with two new programs, Dario Women and Dario Sleep. The company expects rollouts to Fortune 500 clients in Fall 2026 and recurring revenue per engaged member per month to start in Q4 2026, with provider-backed care revenue expected end-2026 into early 2027.

DarioHealth Corp. (NASDAQ: DRIO) launched an Integrated GLP-1 Program combining its AI chronic care platform with provider-backed clinical care from Beluga Health. The offering adds licensed evaluation, prescribing of FDA-approved GLP-1s, and ongoing oversight in one platform. Availability is expected in Fall 2026, with revenue starting late 2026 and ramping through 2027.

Matheis Dennis purchased 14,430 shares of DarioHealth Corp. (DRIO) at $6.93 on 2026-07-23.

A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.